Article Sidebar

PDF
Date Published: 15/06/2023
Abstract Views: 442
Views PDF: 262
DOI: https://doi.org/10.51298/vmj.v527i1.5613
Issue
Vol. 527 No. 1 (2023)
Section
Các bài báo
How to Cite
Nguyễn, V. D. ., & Châu , H. H. . (2023). EFFICIENCY OF ENDOSCOPIC THERAPY WITH PROTON PUMP INHIBITORS IN PATIENTS WITH BLEEDING PEPTIC ULCER. Vietnam Medical Journal, 527(1). https://doi.org/10.51298/vmj.v527i1.5613

EFFICIENCY OF ENDOSCOPIC THERAPY WITH PROTON PUMP INHIBITORS IN PATIENTS WITH BLEEDING PEPTIC ULCER

Văn Dũng Nguyễn1,, Hữu Hầu Châu 1
1 Nhat Tan hospital

Main Article Content

Abstract

Objectives: Efficacy of endoscopic therapy in combination with proton pump inhibitors in patients with gastrointestinal bleeding due to peptic ulcer. Methods: Retrospective and prospective study of interventional endoscopic treatment in patients with bleeding complications due to peptic ulcer in 23 months from the beginning of Jan. 2020 to the end of Nov. 2022 with 48 patients at Nhat Tan hospital, An Giang province. Results: Male patients with peptic ulcer had more GI complications than female patients with a ratio of 5:1. Age of male patients with bleeding peptic ulcer is younger than female patients was 22 to 94 versus 54 to 84. When classifying bleeding peptic ulcer according to Forrest, we only encountered types F1a, F1b and F2a with rates of 16.7%, 31.2% and 52.1%, respectively. Classification of hemorrhagic peptic ulcers: Duodenal ulcer accounted for 41.7% and gastric ulcer for 58.3%, the ratio of duodenal/gastric ulcer was 0.71%. During the study, only 1 case of peptic ulcer (2.1%) had fatal by bleeding complication and 2 cases required second endoscopic intervention (4.3%). Conclusion: Peptic ulcer with bleeding complications in female patients occurred at a later age than male patients (58-84 versus 22-94). Duodenal ulcer is less than gastric ulcer with a ratio of 0.71%. Mortality and recurrent bleeding requiring second endoscopy were rare with rates of 2.1% and 4.3%, respectively.

Article Details

Keywords

Gastroduodenal ulcer, proton pump inhibitor, endoscopic therapy, gastroduodenal bleeding

References

1. Xie X, Ren K, Zhou Z, Dang C, Zhang H. The global, regional and national burden of peptic ulcer disease from 1990 to 2019: a population-based study. BMC Gastroenterology, Vol. 22: 58, 10 Feb, 2022.
2. Vakil NB, Feldman M, Grover S. Peptic ulcer disease: Clinical manifestations and diagnosis. UpToDate, Oct 2022
3. Saltzman JR, Feldman M, Travis AC. Overview of the treatment of bleeding peptic ulcers. UpToDate, Oct 2022
4. Mille M, Engelhardt T, Stier A. Bleeding Duodenal Ulcer: Strategies in High-Risk Ulcers. Clinical Therapeutic Review. Visc Med 2021;37:52–62.
5. Laine L, Barkun AN, Saltzman JR, Martel M, Grigorios I. Leontiadis GI. ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding, Am J Gastroenterol 2021;116:899–917.
6. Cheng HC, Sheu BS. Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits. World J Gastrointest Endosc 2011 March 16; 3(3): 49-56
7. Chatten K, Purssell H, Banerjee AK, Soteriadou S, Ang Y. Glasgow Blatchford Score and risk stratifications in acute upper gastrointestinal bleed: can we extend this to 2 for urgent outpatient management? Clinical Medicine 2018 Vol 18, No 2: 118–22.
8. Huỳnh Hiếu Tâm. Nghiên cứu hiệu quả của tiêm hoặc kẹp cầm máu qua nội soi phối hợp với thuốc ức chế bơm proton liều cao tĩnh mạch ở bệnh nhân xuất huyết tiêu hóa do loét dạ dày tá tràng. Luận án TSYH, Đại học Y khoa Huế, 2019.